Search

Your search keyword '"Hebbar, Mohamed"' showing total 305 results
Start Over Author "Hebbar, Mohamed"
305 results on '"Hebbar, Mohamed"'

1. Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life

Author

Balayssac, David, Kerckhove, Nicolas, Selvy, Marie, Pereira, Bruno, Gonneau, Coralie, Pétorin, Caroline, Vimal-Baguet, Agnès, Melnikov, Sergey, Kullab, Sharif, Hebbar, Mohamed, Bouché, Olivier, Slimano, Florian, Bourgeois, Vincent, Lebrun-Ly, Valérie, Thuillier, Frédéric, Mazard, Thibault, Tavan, David, Benmammar, Kheir-Eddine, Monange, Brigitte, Ramdani, Mohamed, Péré-Vergé, Denis, Huet-Penz, Floriane, Bedjaoui, Ahmed, Genty, Florent, Leyronnas, Cécile, Pezet, Denis, and Martin, Vincent

Published
2024
Full Text
View/download PDF

2. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial

Author

Adam, René, Piedvache, Céline, Chiche, Laurence, Adam, Jean Philippe, Salamé, Ephrem, Bucur, Petru, Cherqui, Daniel, Scatton, Olivier, Granger, Victoire, Ducreux, Michel, Cillo, Umberto, Cauchy, François, Mabrut, Jean-Yves, Verslype, Chris, Coubeau, Laurent, Hardwigsen, Jean, Boleslawski, Emmanuel, Muscari, Fabrice, Jeddou, Heithem, Pezet, Denis, Heyd, Bruno, Lucidi, Valerio, Geboes, Karen, Lerut, Jan, Majno, Pietro, Grimaldi, Lamiae, Levi, Francis, Lewin, Maïté, Gelli, Maximiliano, Adam, René, Piedvache, Céline, Chiche, Laurence, Adam, Jean Philippe, Salamé, Ephrem, Bucur, Petru, Cherqui, Daniel, Scatton, Olivier, Granger, Victoire, Ducreux, Michel, Cillo, Umberto, Cauchy, François, Mabrut, Jean-Yves, Cauchy, François, Mabrut, Jean-Yves, Verslype, Chris, Coubeau, Laurent, Hardwigsen, Jean, Boleslawski, Emmanuel, Muscari, Fabrice, Jeddou, Heithem, Pezet, Denis, Heyd, Bruno, Lucidi, Valerio, Geboes, Karen, Lerut, Jan, Majno, Pietro, Grimaldi, Lamiae, Levi, Francis, Lewin, Maïté, Gelli, Maximiliano, Soubrane, Olivier, Lesurtel, Mickael, Bachet, Jean Baptsite, Lesourd, Samuel, Jary, Marine, Bouattour, Mohamed, Lonardi, Sara, Hebbar, Mohamed, Boudjema, Karim, Smith, Denis, Chirica, Mircea, Lecomte, Thierry, Borg, Chirstophe, Guimbaud, Rosine, Taieb, Julien, Burra, Patrizia, Rougier, Philippe, and Figueras, Joan

Abstract

Despite the increasing efficacy of chemotherapy, permanently unresectable colorectal liver metastases are associated with poor long-term survival. We aimed to assess whether liver transplantation plus chemotherapy could improve overall survival.

Published
2024
Full Text
View/download PDF

4. Adenocarcinoma of the oesophagogastric junction Siewert II: An oesophageal cancer better cured with total gastrectomy

Author

Arnaud, Jean Pierre, Balon, Jean Michel, Bonnetain, Frank, Borie, Frederic, Brachet, Dorothée, Brigand, Cécile, Carrere, Nicolas, D'Journo, Xavier Benoit, Dechelotte, Pierre, Delpero, Jean Robert, Dhari, Abdenaceur, Fabre, Sylvain, Fernandez, Manuel, Flamein, Renaud, Gillet, Brigitte, Glaise, Aude, Glehen, Olivier, Goéré, Diane, Guilbert, Marie, Guiramand, Jérôme, Hebbar, Mohamed, Huten, Noël, Leteurtre, Emmanuelle, Kraft, Kevin, Louis, Damien, Mabrut, Jean Yves, Mathieu, Benjamin, Michalak, Sophie, Michot, Francis, Millat, Bertrand, Lefevre, Jeremie H., Peschaud, Fédérique, Pezet, Denis, Pichot-Delahaye, Virginie, Pocard, Marc, Poisson, Ariane, Prudhomme, Michel, Regimbeau, Jean Marc, Thiébot, Timothée, Thomas, Pascal- Alexandre, Tsilividis, Basile, Vandois, Florence, Voron, Thibault, Gronnier, Caroline, Pasquer, Arnaud, Thereaux, Jeremie, Gagniere, Johan, Lebreton, Gil, Meunier, Bernard, Collet, Denis, Piessen, Guillaume, and Paye, François

Published
2019
Full Text
View/download PDF

6. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Luft, Alexander V., Karaseva, Nina A., Kowalyszyn, Rubén Dario, Hernandez, Carlos Alberto, Csoszi, Tibor, De Vita, Ferdinando, Pfeiffer, Per, Sugimoto, Naotoshi, Kocsis, Judit, Csilla, Andràs, Bodoky, Gyorgy, Garnica Jaliffe, Georgina, Protsenko, Svetlana, Madi, Ayman, Wojcik, Elzbieta, Brenner, Baruch, Folprecht, Gunnar, Sarosiek, Tomasz, Peltola, Katriina Johanna, Bono, Peter, Ayala, Hubert, Aprile, Giuseppe, Gerardo, Cardellino Giovanni, Huitzil Melendez, Fidel David, Falcone, Alfredo, Di Costanzo, Francesco, Tehfe, Moustapha, Mineur, Laurent, García Alfonso, Pilar, Obermannova, Radka, Senellart, Hélène, Petty, Russell, Samuel, Leslie, Acs, Peter Istvan, Hussein, Maen Abdelkarim, Nechaeva, Marina N., Erdkamp, F.L.G., Won, Elizabeth, Bendell, Johanna Chock, Gallego Plazas, Javier, Lorenzen, Sylvie, Melichar, Bohuslav, Escudero, Miguel Angel, Pezet, Denis, Phelip, Jean-Marc, Kaen, Diego Lucas, Reeves, James A. Jr, Longo Muñoz, Federico, Madhusudan, Srinivasan, Barone, Carlo, Fein, Luis Enrique, Gomez Villanueva, Angel, Hebbar, Mohamed, Prausova, Jana, Visa Turmo, Laura, Vidal Barrull, Joana, Yilmaz, Mette Karen Nytoft, Beny, Alex, Van Laarhoven, H.M.W., DiCarlo, Brian Anthony, Esaki, Taito, Fujitani, Kazumasa, Geboes, Karen, Geva, Ravit, Kadowaki, Shigenori, Leong, Stephen, Machida, Nozomu, Raj, Moses Sundar, Ramirez Godinez, Francisco Javier, Ruzsa, Agnes, Ford, Hugo, Lawler, William E., Maisey, Nicolas Robert, Petera, Jiri, Shacham-Shmueli, Einat, Sinapi, Isabelle, Yamaguchi, Kensei, Hara, Hiroki, Beck, Joseph Thaddeus, Błasińska-Morawiec, Maria, Villalobos Valencia, Ricardo, Alcindor, Thierry, Bajaj, Madhuri, Berry, Scott, Gomez, Christina Maria, Dammrich, Daniel, Patel, Ravindranath, Taieb, Julien, Ten Tije, A.J., Burkes, Ronald L., Cabanillas, Fernando, Firdaus, Irfan, Chua, Cynthia Coo, Hironaka, Shuichi, Hofheinz, Ralf-Dieter, Lim, Howard J., Nordsmark, Marianne, Piko, Bela, Verma, Udit, Wadsley, Jonathan, Yukisawa, Seigo, Gutiérrez Delgado, Francisco, Denlinger, Crystal S., Kallio, Raija, Pikiel, Joanna, Wojcik-Tomaszewska, Joanna, Brezden-Masley, Christine, Jang, Raymond Woo-Jun, Pribylova, Jana, Sakai, Daisuke, Bartoli, Maria Alejandra, Cats, A., Grootscholten, M.I., Dichmann, Robert Andrew, Hool, Hugo, Shaib, Walid, Tsuji, Akihito, Van den Eynde, Marc, Velez-Cortez, Hector, Asmis, Timothy R., Fuchs, Charles S, Shitara, Kohei, Di Bartolomeo, Maria, Lonardi, Sara, Al-Batran, Salah-Eddin, Van Cutsem, Eric, Ilson, David H, Alsina, Maria, Chau, Ian, Lacy, Jill, Ducreux, Michel, Mendez, Guillermo Ariel, Alavez, Alejandro Molina, Takahari, Daisuke, Mansoor, Wasat, Enzinger, Peter C, Gorbounova, Vera, Wainberg, Zev A, Hegewisch-Becker, Susanna, Ferry, David, Lin, Ji, Carlesi, Roberto, Das, Mayukh, and Shah, Manish A

Published
2019
Full Text
View/download PDF

9. Supplementary Figure Legend from Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis

Author

Touil, Yasmine, primary, Igoudjil, Wassila, primary, Corvaisier, Matthieu, primary, Dessein, Anne-Frédérique, primary, Vandomme, Jérôme, primary, Monté, Didier, primary, Stechly, Laurence, primary, Skrypek, Nicolas, primary, Langlois, Carole, primary, Grard, Georges, primary, Millet, Guillaume, primary, Leteurtre, Emmanuelle, primary, Dumont, Patrick, primary, Truant, Stéphanie, primary, Pruvot, François-René, primary, Hebbar, Mohamed, primary, Fan, Fan, primary, Ellis, Lee M., primary, Formstecher, Pierre, primary, Van Seuningen, Isabelle, primary, Gespach, Christian, primary, Polakowska, Renata, primary, and Huet, Guillemette, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 2 from Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis

Author

Touil, Yasmine, primary, Igoudjil, Wassila, primary, Corvaisier, Matthieu, primary, Dessein, Anne-Frédérique, primary, Vandomme, Jérôme, primary, Monté, Didier, primary, Stechly, Laurence, primary, Skrypek, Nicolas, primary, Langlois, Carole, primary, Grard, Georges, primary, Millet, Guillaume, primary, Leteurtre, Emmanuelle, primary, Dumont, Patrick, primary, Truant, Stéphanie, primary, Pruvot, François-René, primary, Hebbar, Mohamed, primary, Fan, Fan, primary, Ellis, Lee M., primary, Formstecher, Pierre, primary, Van Seuningen, Isabelle, primary, Gespach, Christian, primary, Polakowska, Renata, primary, and Huet, Guillemette, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 2 from Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis

Author

Touil, Yasmine, primary, Igoudjil, Wassila, primary, Corvaisier, Matthieu, primary, Dessein, Anne-Frédérique, primary, Vandomme, Jérôme, primary, Monté, Didier, primary, Stechly, Laurence, primary, Skrypek, Nicolas, primary, Langlois, Carole, primary, Grard, Georges, primary, Millet, Guillaume, primary, Leteurtre, Emmanuelle, primary, Dumont, Patrick, primary, Truant, Stéphanie, primary, Pruvot, François-René, primary, Hebbar, Mohamed, primary, Fan, Fan, primary, Ellis, Lee M., primary, Formstecher, Pierre, primary, Van Seuningen, Isabelle, primary, Gespach, Christian, primary, Polakowska, Renata, primary, and Huet, Guillemette, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 1 from Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis

Author

Touil, Yasmine, primary, Igoudjil, Wassila, primary, Corvaisier, Matthieu, primary, Dessein, Anne-Frédérique, primary, Vandomme, Jérôme, primary, Monté, Didier, primary, Stechly, Laurence, primary, Skrypek, Nicolas, primary, Langlois, Carole, primary, Grard, Georges, primary, Millet, Guillaume, primary, Leteurtre, Emmanuelle, primary, Dumont, Patrick, primary, Truant, Stéphanie, primary, Pruvot, François-René, primary, Hebbar, Mohamed, primary, Fan, Fan, primary, Ellis, Lee M., primary, Formstecher, Pierre, primary, Van Seuningen, Isabelle, primary, Gespach, Christian, primary, Polakowska, Renata, primary, and Huet, Guillemette, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table 1 from Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis

Author

Touil, Yasmine, primary, Igoudjil, Wassila, primary, Corvaisier, Matthieu, primary, Dessein, Anne-Frédérique, primary, Vandomme, Jérôme, primary, Monté, Didier, primary, Stechly, Laurence, primary, Skrypek, Nicolas, primary, Langlois, Carole, primary, Grard, Georges, primary, Millet, Guillaume, primary, Leteurtre, Emmanuelle, primary, Dumont, Patrick, primary, Truant, Stéphanie, primary, Pruvot, François-René, primary, Hebbar, Mohamed, primary, Fan, Fan, primary, Ellis, Lee M., primary, Formstecher, Pierre, primary, Van Seuningen, Isabelle, primary, Gespach, Christian, primary, Polakowska, Renata, primary, and Huet, Guillemette, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Methods from Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis

Author

Touil, Yasmine, primary, Igoudjil, Wassila, primary, Corvaisier, Matthieu, primary, Dessein, Anne-Frédérique, primary, Vandomme, Jérôme, primary, Monté, Didier, primary, Stechly, Laurence, primary, Skrypek, Nicolas, primary, Langlois, Carole, primary, Grard, Georges, primary, Millet, Guillaume, primary, Leteurtre, Emmanuelle, primary, Dumont, Patrick, primary, Truant, Stéphanie, primary, Pruvot, François-René, primary, Hebbar, Mohamed, primary, Fan, Fan, primary, Ellis, Lee M., primary, Formstecher, Pierre, primary, Van Seuningen, Isabelle, primary, Gespach, Christian, primary, Polakowska, Renata, primary, and Huet, Guillemette, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 2 from Autocrine Induction of Invasive and Metastatic Phenotypes by the MIF-CXCR4 Axis in Drug-Resistant Human Colon Cancer Cells

Author

Dessein, Anne-Frédérique, primary, Stechly, Laurence, primary, Jonckheere, Nicolas, primary, Dumont, Patrick, primary, Monté, Didier, primary, Leteurtre, Emmanuelle, primary, Truant, Stéphanie, primary, Pruvot, François-René, primary, Figeac, Martin, primary, Hebbar, Mohamed, primary, Lecellier, Charles-Henri, primary, Lesuffleur, Thécla, primary, Dessein, Rodrigue, primary, Grard, Georges, primary, Dejonghe, Marie-José, primary, de Launoit, Yvan, primary, Furuichi, Yasuhiro, primary, Prévost, Grégoire, primary, Porchet, Nicole, primary, Gespach, Christian, primary, and Huet, Guillemette, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 1 from Autocrine Induction of Invasive and Metastatic Phenotypes by the MIF-CXCR4 Axis in Drug-Resistant Human Colon Cancer Cells

Author

Dessein, Anne-Frédérique, primary, Stechly, Laurence, primary, Jonckheere, Nicolas, primary, Dumont, Patrick, primary, Monté, Didier, primary, Leteurtre, Emmanuelle, primary, Truant, Stéphanie, primary, Pruvot, François-René, primary, Figeac, Martin, primary, Hebbar, Mohamed, primary, Lecellier, Charles-Henri, primary, Lesuffleur, Thécla, primary, Dessein, Rodrigue, primary, Grard, Georges, primary, Dejonghe, Marie-José, primary, de Launoit, Yvan, primary, Furuichi, Yasuhiro, primary, Prévost, Grégoire, primary, Porchet, Nicole, primary, Gespach, Christian, primary, and Huet, Guillemette, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 1 from Autocrine Induction of Invasive and Metastatic Phenotypes by the MIF-CXCR4 Axis in Drug-Resistant Human Colon Cancer Cells

Author

Dessein, Anne-Frédérique, primary, Stechly, Laurence, primary, Jonckheere, Nicolas, primary, Dumont, Patrick, primary, Monté, Didier, primary, Leteurtre, Emmanuelle, primary, Truant, Stéphanie, primary, Pruvot, François-René, primary, Figeac, Martin, primary, Hebbar, Mohamed, primary, Lecellier, Charles-Henri, primary, Lesuffleur, Thécla, primary, Dessein, Rodrigue, primary, Grard, Georges, primary, Dejonghe, Marie-José, primary, de Launoit, Yvan, primary, Furuichi, Yasuhiro, primary, Prévost, Grégoire, primary, Porchet, Nicole, primary, Gespach, Christian, primary, and Huet, Guillemette, primary

Published
2023
Full Text
View/download PDF

18. Data from Autocrine Induction of Invasive and Metastatic Phenotypes by the MIF-CXCR4 Axis in Drug-Resistant Human Colon Cancer Cells

Author

Dessein, Anne-Frédérique, primary, Stechly, Laurence, primary, Jonckheere, Nicolas, primary, Dumont, Patrick, primary, Monté, Didier, primary, Leteurtre, Emmanuelle, primary, Truant, Stéphanie, primary, Pruvot, François-René, primary, Figeac, Martin, primary, Hebbar, Mohamed, primary, Lecellier, Charles-Henri, primary, Lesuffleur, Thécla, primary, Dessein, Rodrigue, primary, Grard, Georges, primary, Dejonghe, Marie-José, primary, de Launoit, Yvan, primary, Furuichi, Yasuhiro, primary, Prévost, Grégoire, primary, Porchet, Nicole, primary, Gespach, Christian, primary, and Huet, Guillemette, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Methods, Figure Legends 1 from Autocrine Induction of Invasive and Metastatic Phenotypes by the MIF-CXCR4 Axis in Drug-Resistant Human Colon Cancer Cells

Author

Dessein, Anne-Frédérique, primary, Stechly, Laurence, primary, Jonckheere, Nicolas, primary, Dumont, Patrick, primary, Monté, Didier, primary, Leteurtre, Emmanuelle, primary, Truant, Stéphanie, primary, Pruvot, François-René, primary, Figeac, Martin, primary, Hebbar, Mohamed, primary, Lecellier, Charles-Henri, primary, Lesuffleur, Thécla, primary, Dessein, Rodrigue, primary, Grard, Georges, primary, Dejonghe, Marie-José, primary, de Launoit, Yvan, primary, Furuichi, Yasuhiro, primary, Prévost, Grégoire, primary, Porchet, Nicole, primary, Gespach, Christian, primary, and Huet, Guillemette, primary

Published
2023
Full Text
View/download PDF

20. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer

Author

Bouchahda, Mohamed, Boige, Valérie, Smith, Denis, Karaboué, Abdoulaye, Ducreux, Michel, Hebbar, Mohamed, Lepère, Céline, Focan, Christian, Guimbaud, Rosine, Innominato, Pasquale, Awad, Sameh, Carvalho, Carlos, Tumolo, Salvatore, Truant, Stephanie, De Baere, Thierry, Castaing, Denis, Rougier, Philippe, Morère, Jean-François, Taieb, Julien, Adam, René, and Lévi, Francis

Published
2016
Full Text
View/download PDF

29. Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy

Author

Kerckhove, Nicolas, primary, Selvy, Marie, additional, Lambert, Céline, additional, Gonneau, Coralie, additional, Feydel, Gabrielle, additional, Pétorin, Caroline, additional, Vimal-Baguet, Agnès, additional, Melnikov, Sergey, additional, Kullab, Sharif, additional, Hebbar, Mohamed, additional, Bouché, Olivier, additional, Slimano, Florian, additional, Bourgeois, Vincent, additional, Lebrun-Ly, Valérie, additional, Thuillier, Frédéric, additional, Mazard, Thibault, additional, Tavan, David, additional, Benmammar, Kheir Eddine, additional, Monange, Brigitte, additional, Ramdani, Mohamed, additional, Péré-Vergé, Denis, additional, Huet-Penz, Floriane, additional, Bedjaoui, Ahmed, additional, Genty, Florent, additional, Leyronnas, Cécile, additional, Busserolles, Jérôme, additional, Trévis, Sophie, additional, Pinon, Vincent, additional, Pezet, Denis, additional, and Balayssac, David, additional

Published
2021
Full Text
View/download PDF

30. Spatial heterogeneity of KRAS mutations in colorectal cancers in northern France

Author

Turpin, Anthony, Genin, Michael, Hebbar, Mohamed, Occelli, Florent, Lanier, Caroline, Vasseur, Francis, Descarpentries, Clotilde, Pannier, Diane, Ploquin, Anne, Impact de l'environnement chimique sur la santé humaine - ULR 4483 (IMPECS), and Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)

Subjects
highways, Cancer Management and Research, KRAS mutation, [SDV.CAN]Life Sciences [q-bio]/Cancer, colorectal cancer, spatial scan statistics, neoplasms, carcinogens, ComputingMilieux_MISCELLANEOUS, digestive system diseases, Original Research
Abstract

Anthony Turpin,1–3 Michael Genin,4 Mohamed Hebbar,1,2 Florent Occelli,5 Caroline Lanier,5 Francis Vasseur,4 Clotilde Descarpentries,6 Diane Pannier,7 Anne Ploquin1 1Medical oncology unit, Hôpital Claude Huriez, F-59000 Lille, France; 2Lille University Medical School, Université Lille Nord de France, Lille, France; 3University Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - Mechanisms of Tumorigenesis and Target Therapies, F-59021 Lille, France; 4EA 2694-Santé Publique: épidémiologie et qualité des soins, University Lille, CHU Lille, 59000 Lille, France; 5EA 4483 - Impact de l’environnement chimique sur la santé humaine, University of Lille, 59000 Lille, France; 6Division of Biochemistry and Molecular Biology, Oncology and Molecular Genetics Laboratory, CHU Lille, Lille, France; 7Department of Medical Oncology, Centre Oscar Lambret, Lille, F-59000, FranceCorrespondence: Anthony TurpinMedical Oncology Unit, Hôpital Claude Huriez, Rue Michel Polonovski, Lille Cedex 59037, FranceTel +33 32 044 5461Fax +33 32 044 4381Email anthony.turpin@chru-lille.frBackground: Somatic mutations in the KRAS gene are the most common oncogenic mutations found in human cancers. However, no clinical features have been linked to KRAS mutations in colorectal cancer [CRC].Purpose: In this study, we attempted to identify the potential geographical population clusters of KRAS mutations in CRC patients in northern France.Patients and methods: All patients with CRC who were identified to have KRAS mutations between 2008 and 2014 at the Regional Molecular Biology Platform at Lille University Hospital were included. 2,486 patients underwent a KRAS status available, with 40.9% of CRC with KRAS mutations in northern France. We retrospectively collected demographic and geographic data from these patients. The proportions of KRAS mutation were smoothed to take into account the variability related to low frequencies and spatial autocorrelation. Geographical clusters were searched using spatial scan statistical models.Results: A mutation at KRAS codon 12 or 13 was found in 1,018 patients [40.9%]. We report 5 clusters of over-incidence but only one elongated cluster that was statistically significant [Cluster 1; proportion of KRAS mutation among CRC: 0.4570; RR=1.29; P=0.0314]. We made an ecological study which did not highlight a significant association between KRAS mutations and the distance to the Closest Waste Incineration Plant, and between KRAS mutations and The French Ecological Deprivation Index but few socio-economic and environmental data were available.Conclusion: There was a spatial heterogeneity and a greater frequency of KRAS mutations in some areas close to major highways and big cities in northern France. These data demand deeper epidemiological investigations to identify environmental factors such as air pollution as key factors in the occurrence of KRAS mutations.Keywords: colorectal cancer, KRAS mutation, spatial scan statistics, carcinogens, highways

Published
2019

35. Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study

Author

Turpin, Anthony, primary, de Baere, Thierry, additional, Heurgué, Alexandra, additional, Le Malicot, Karine, additional, Ollivier-Hourmand, Isabelle, additional, Lecomte, Thierry, additional, Perrier, Hervé, additional, Vergniol, Julien, additional, Sefrioui, David, additional, Rinaldi, Yves, additional, Edeline, Julien, additional, Jouve, Jean-Louis, additional, Silvain, Christine, additional, Becouarn, Yves, additional, Dauvois, Barbara, additional, Baconnier, Mathieu, additional, Debette-Gratien, Maryline, additional, Deplanque, Gael, additional, Dharancy, Sébastien, additional, Lepage, Côme, additional, and Hebbar, Mohamed, additional

Published
2021
Full Text
View/download PDF

41. Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results

Author

Bascoul-Mollevi, Caroline, primary, Barbieri, Antoine, additional, Bourgier, Céline, additional, Conroy, Thierry, additional, Chauffert, Bruno, additional, Hebbar, Mohamed, additional, Jacot, William, additional, Juzyna, Beata, additional, De Forges, Hélène, additional, Gourgou, Sophie, additional, Bonnetain, Franck, additional, Touraine, Célia, additional, and Anota, Amélie, additional

Published
2020
Full Text
View/download PDF

42. Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study

Author

Selvy, Marie, primary, Pereira, Bruno, additional, Kerckhove, Nicolas, additional, Gonneau, Coralie, additional, Feydel, Gabrielle, additional, Pétorin, Caroline, additional, Vimal-Baguet, Agnès, additional, Melnikov, Sergey, additional, Kullab, Sharif, additional, Hebbar, Mohamed, additional, Bouché, Olivier, additional, Slimano, Florian, additional, Bourgeois, Vincent, additional, Lebrun-Ly, Valérie, additional, Thuillier, Frédéric, additional, Mazard, Thibault, additional, Tavan, David, additional, Benmammar, Kheir Eddine, additional, Monange, Brigitte, additional, Ramdani, Mohamed, additional, Péré-Vergé, Denis, additional, Huet-Penz, Floriane, additional, Bedjaoui, Ahmed, additional, Genty, Florent, additional, Leyronnas, Cécile, additional, Busserolles, Jérôme, additional, Trevis, Sophie, additional, Pinon, Vincent, additional, Pezet, Denis, additional, and Balayssac, David, additional

Published
2020
Full Text
View/download PDF

43. Adenocarcinoma of the oesophagogastric junction Siewert II: An oesophageal cancer better cured with total gastrectomy

Author

Voron, Thibault, primary, Gronnier, Caroline, additional, Pasquer, Arnaud, additional, Thereaux, Jeremie, additional, Gagniere, Johan, additional, Lebreton, Gil, additional, Meunier, Bernard, additional, Collet, Denis, additional, Piessen, Guillaume, additional, Paye, François, additional, Arnaud, Jean Pierre, additional, Balon, Jean Michel, additional, Bonnetain, Frank, additional, Borie, Frederic, additional, Brachet, Dorothée, additional, Brigand, Cécile, additional, Carrere, Nicolas, additional, D'Journo, Xavier Benoit, additional, Dechelotte, Pierre, additional, Delpero, Jean Robert, additional, Dhari, Abdenaceur, additional, Fabre, Sylvain, additional, Fernandez, Manuel, additional, Flamein, Renaud, additional, Gillet, Brigitte, additional, Glaise, Aude, additional, Glehen, Olivier, additional, Goéré, Diane, additional, Guilbert, Marie, additional, Guiramand, Jérôme, additional, Hebbar, Mohamed, additional, Huten, Noël, additional, Leteurtre, Emmanuelle, additional, Kraft, Kevin, additional, Louis, Damien, additional, Mabrut, Jean Yves, additional, Mathieu, Benjamin, additional, Michalak, Sophie, additional, Michot, Francis, additional, Millat, Bertrand, additional, Lefevre, Jeremie H., additional, Peschaud, Fédérique, additional, Pezet, Denis, additional, Pichot-Delahaye, Virginie, additional, Pocard, Marc, additional, Poisson, Ariane, additional, Prudhomme, Michel, additional, Regimbeau, Jean Marc, additional, Thiébot, Timothée, additional, Thomas, Pascal- Alexandre, additional, Tsilividis, Basile, additional, and Vandois, Florence, additional

Published
2019
Full Text
View/download PDF

46. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer

Author

Bennouna, Jaafar, Hiret, Sandrine, Bertaut, Aurélie, Bouche, Olivier, Deplanque, Gaël, Borel, Christian, François, Eric, Conroy, Thierry, Ghiringhelli, François, Des Guetz, Gaëtan, Seitz, Jean-François, Artru, Pascal, Hebbar, Mohamed, Stanbury, Trevor, Denis, Marc, Adenis, Antoine, Borg, Christophe, Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Département d'oncologie médicale [Centre Georges-François Leclerc], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Saint-Joseph [Marseille], CRLCC Paul Strauss, Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'oncologie digestive et hépato-gastro-entérologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital privé Jean Mermoz, Service d'oncologie médicale (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), R&D Unicancer [Paris], Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université de Lille-UNICANCER, and Herrada, Anthony

Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience; Importance:Second-line treatment with chemotherapy plus bevacizumab or cetuximab is a valid option for metastatic colorectal cancer.Objective:To evaluate the progression-free survival (PFS) rate at 4 months with chemotherapy plus bevacizumab vs cetuximab for patients with progression of metastatic colorectal cancer after bevacizumab plus chemotherapy.Design, Setting, and Participants:A prospective, open-label, multicenter, randomized phase 2 trial was conducted from December 14, 2010, to May 5, 2015. The main eligibility criterion was disease progression after bevacizumab plus fluorouracil with irinotecan or oxaliplatin in patients with wild-type KRAS exon 2 metastatic colorectal cancer. All analyses were performed on the modified intent-to-treat population.Interventions:Patients were randomized to arm A (FOLFIRI [fluorouracil and folinic acid combined with irinotecan] or modified FOLFOX6 [fluorouracil and folinic acid combined with oxaliplatin] plus bevacizumab) or arm B (FOLFIRI or modified FOLFOX6 plus cetuximab); the second-line chemotherapy regimen was chosen according to first-line treatment (crossover).Main Outcomes and Measures:The primary end point was the 4-month PFS rate. Secondary end points included safety, objective response rate, overall survival, and PFS.Results:A total of 132 patients (47 women and 85 men; median age, 63.0 years [range, 33.0-84.0 years]; 74 patients with an Eastern Cooperative Oncology Group performance status of 0, 54 patients with a performance status of 1, and 4 patients with unknown performance status) were included at 25 sites. The 4-month PFS rate was 80.3% (95% CI, 68.0%-88.3%) in arm A and 66.7% (95% CI, 53.6%-76.8%) in arm B. The median PFS was 7.1 months (95% CI, 5.7-8.2 months) in arm A and 5.6 months (95% CI, 4.2-6.5 months) in arm B (hazard ratio, 0.71; 95% CI, 0.50-1.02; P = .06), and the median overall survival was 15.8 months (95% CI, 9.5-22.3 months) in arm A and 10.4 months (95% CI, 7.0-16.2 months) in arm B (hazard ratio, 0.69; 95% CI, 0.46-1.04; P = .08). A central analysis of KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4), and BRAF (V600) was performed for 95 tumor samples. Eighty-one patients had wild-type KRAS and wild-type NRAS tumors.Conclusions and Relevance:The results of the PRODIGE18 (Partenariat de Recherche en Oncologie DIGEstive) study showed a nonsignificant difference but favored continuation of bevacizumab with chemotherapy crossover for patients with wild-type RAS metastatic colorectal cancer that progressed with first-line bevacizumab plus chemotherapy.Trial Registration:ClinicalTrials.gov identifier: NCT01442649 and clinicaltrialsregister.eu identifier: EUDRACT 2009-012942-22.

Published
2019

47. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Author

Conroy, Thierry, Hammel, Pascal, Hebbar, Mohamed, Ben Abdelghani, Meher, Wei, Alice, Raoul, Jean-Luc, Choné, Laurence, Francois, Eric, Artru, Pascal, Biagi, James, Lecomte, Thierry, Assenat, Eric, Faroux, Roger, Ychou, Marc, Volet, Julien, Sauvanet, Alain, Breysacher, Gilles, Di Fiore, Frédéric, Cripps, Christine, Kavan, Petr, Texereau, Patrick, Bouhier-Leporrier, Karine, Khemissa-Akouz, Faiza, Legoux, Jean-Louis, Juzyna, Beata, Gourgou, Sophie, O'Callaghan, Christopher, Jouffroy-Zeller, Claire, Rat, Patrick, Malka, David, Castan, Florence, Bachet, Jean-Baptiste, Trials Group, Canadian Cancer, Group, Unicancer-GI–PRODIGE, Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Claude Huriez [Lille], CHU Lille, CRLCC Paul Strauss, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Hôpital privé Jean Mermoz, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Reims (CHU Reims), Service de chirurgie hepato-pancreato-biliaire, Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Louis Pasteur [Colmar] (CH Colmar), CHU Rouen, Normandie Université (NU), CHU Mont de Marsan, Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Saint Jean de Perpignan, Centre Hospitalier Régional d'Orléans (CHRO), R&D UNICANCER, Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCL/UNICANCER), UNICANCER-UNICANCER, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Oncologie digestive, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de Cancérologie de Lorraine - Alexis Vautrin (ICL), Hôpital Beaujon-Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Hôpital Claude Huriez, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CRLCC Antoine Lacassagne, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon, Centre Hospitalier Régional d'Orléans (CHR), Service de Gastroentérologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Adult, Male, medicine.medical_specialty, FOLFIRINOX, Leucovorin, [SDV.CAN]Life Sciences [q-bio]/Cancer, Irinotecan, Deoxycytidine, Gastroenterology, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Pancreatic cancer, Antineoplastic Combined Chemotherapy Protocols, Organometallic Compounds, medicine, Adjuvant therapy, Humans, Prospective Studies, Survival rate, Aged, Proportional Hazards Models, Aged, 80 and over, business.industry, Combination chemotherapy, General Medicine, Middle Aged, medicine.disease, Gemcitabine, 3. Good health, Oxaliplatin, Pancreatic Neoplasms, Drug Combinations, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, Fluorouracil, Folfirinox Regimen, Lung Diseases, Interstitial, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, medicine.drug
Abstract

International audience; BACKGROUND:Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.METHODS:We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety.RESULTS:At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results